Global Genomics signs collaboration agreement with Rheoscience A/S

Global Genomics signs collaboration agreement with Rheoscience A/S Global Genomics(SM) AB (Stockholm, Sweden) announced today that Rheoscience A/S (Roedovre, Denmark) has entered into an agreement for the use tangerine® gene expression profiling to study targets in metabolic diseases. Ulf Boberg, CEO at Global Genomics stated, "This agreement is yet another confirmation of that researchers are demanding gene expression technologies that provide higher quality information. We are very excited about expanding our customer base and broadening customer awareness." About Rheoscience Rheoscience A/S is a Danish independent biotech company that, apart from own obesity research projects, provides research services within the fields of obesity and diabetes. Unique well-characterized animal models of the metabolic syndrome and internationally recognized scientists ensure fast, versatile and flexible in vivo pharmacology of lead compounds targeting metabolic disorders. About Global Genomics Global Genomics develops and out-licenses innovative tools in functional genomics that provide unique insight into healthy, diseased or drug-treated cells. The company's expertise in advanced molecular biology techniques and computational analysis has resulted in the recent launch of tangerine® gene expression profiling, a proprietary solution that reveals a whole genome expression profile in a single experiment. High coverage and sensitivity ensure complete profiles of expressed genes, giving researchers the ability to study gene regulation in any disease or eukaryotic model, since there is no prerequisite for sequence data. The tangerine technology is based on PCR, capillary electrophoresis, proprietary databases and algorithms that generate gene expression profiles. Incorporating such comprehensive gene expression profiling at key stages in drug discovery significantly improves selection of targets and lead compounds, leading to well-validated drug candidates and expediting development of a strong pharmaceuticals portfolio. Questions regarding this press release or other issues should be directed to Ms. Erika Johnson, Chief Financial Officer, +46 8 50 88 47 03 or Mr. Martin Vidaeus, Manager Market Development, +46 8 50 88 47 29. Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Although based on the company's current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from those expressed herein. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards. ------------------------------------------------------------------------------------------------ The Global Genomics (SM) logo and tangerine (R) are service and registered trademarks, respectively, of Global Genomics AB. ------------------------------------------------------------ Denna information skickades av Waymaker http://www.waymaker.se Följande filer finns att ladda ned: http://www.waymaker.net/bitonline/2004/09/20/20040909BIT21080/wkr0010.pdf